Morepen LaboratoriesQ1 FY25

Morepen Laboratories Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹94.66P/E: 27.5Market Cap: ₹5.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • The company expects to maintain at least 15% to 18% revenue growth.
  • Revenue growth is anticipated to be steady between 15% to 20% annually.
  • Medical devices segment is the fastest growing business, with a CAGR of around 20%-25%, expected to continue.
  • Expansion plans to increase retail outlets from 128,000 to 300,000 across India within three years to boost sales.
  • Focus on backward integration and capacity expansion to support volume growth in glucometers, BP monitors, and APIs.
  • International market penetration is targeted within 2-3 years to significantly enhance growth prospects.
  • New launches planned, including a weight loss OTC product, aiming to capture emerging market segments.
  • EBITDA margins expected to improve by 3% to 4% over the next 2-3 years, supporting profitability alongside revenue growth.
  • Export markets, especially Europe and Asia Pacific, showing strong growth potential with ongoing capacity enhancement.

See what Morepen Laboratories management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • Currently, there is no immediate plan for new acquisitions or fundraising through equity as the recent QIP of INR 200 crores was primarily for capex and working capital.
  • The company is evaluating multiple acquisition opportunities but will consider them only if they add synergy and align with strategy.
  • No immediate debt raise is planned; Morepen Laboratories is currently a debt-free company.
  • The capital raised in the recent QIP is targeted mainly for capacity expansion in APIs and medical devices.
  • Future fundraising through debt or equity will depend on cash surplus and strategic needs, but no specific plans have been announced at this time.

See what Morepen Laboratories management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Currently, Morepen Laboratories has planned a capex of INR 123 crores.
  • Of this, approximately INR 78 crores is allocated for API capacity expansion (from 400 KL to 600 KL).
  • Around INR 40-45 crores is earmarked for medical devices, including backward integration and capacity expansion for glucometers, BP monitors, and weighing scales.
  • Backward integration projects, such as chip manufacturing for medical devices, are underway and expected to show results from Q3/Q4 FY '25.
  • The company is focused on expanding distribution reach across India (especially South and West regions) and tapping into global export markets.
  • Though there is no immediate plan for acquisitions, the company remains open to synergistic acquisitions if suitable opportunities arise.
  • The capital raised through QIP (approx. INR 200 crores) primarily supports these capex plans with a focus on sustained revenue growth (estimated 15%-20% annually) and margin improvement.

Track Morepen Laboratories — get its next earnings analysis in your feed

How does Morepen Laboratories rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisMorepen Laboratories
Rev 3Mar 1

How does Morepen Laboratories rank in Pharmaceuticals & Biotechnology?

Compare Morepen Laboratories against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →